Category Archives: Indian Patent Law

Hepatitis C sufferer warns ‘hundreds of thousands will die’ if India changes patent law in trade deal

By South Asia correspondent James Bennett, ABC News | Apr 2, 2016 India, sometimes dubbed “pharmacy to the developing world”, is facing pressure to change strict patent laws as it negotiates a trade deal with Europe. That would make it easier … Continue reading

Posted in EU-India FTA, FTA, Generics, Hepatitis C, Indian Patent Law, Uncategorized | Leave a comment

Govt. draws flak for decision to allow U.S.- trained patent examiners

By Vidya Krishnan, The Hindu | March 30, 2016 Humanitarian aid organisation Médecins Sans Frontières (Doctors Without Borders) has questioned the Indian government’s decision to have patent officers trained by the United States Patent & Trademark Office after the recent … Continue reading

Posted in Indian Patent Law, Patent examination system, Uncategorized | Leave a comment

Eli Lilly bats for a favourable patent regime in India

Eli Lilly wants a more favourable patent regime that ‘rewards innovation’ and would welcome an open dialogue from the government in this respect New Delhi: Global pharma company Eli Lilly wants a more favourable patent regime in India that “rewards … Continue reading

Posted in Indian Patent Law, Innovation, Special 301 report, Uncategorized | Leave a comment

Pharma company Viiv’s attempt to secure patents for key HIV drugs dolutegravir and cabotegravir opposed in India

‘Patent opposition’ seeks to ensure availability of affordable generics New Delhi/Geneva, 8 February, 2016—People living with HIV have opposed patent applications in India for two important HIV medicines, dolutegravir and cabotegravir.  Médecins Sans Frontières/ Doctors Without Borders (MSF) supports these … Continue reading

Posted in Evergreening, Indian Patent Law, Patent Opposition, Uncategorized | Leave a comment

The pill that costs $9,000 in US sells for $70 in India

Rema Nagarajan, TNN | Feb 7, 2016 And that’s just one leukaemia drug. India’s generic industry has been producing many such life-saving medicines at a fraction of the global price The Hyderabad-based Bharat Biotech might be the first to come out … Continue reading

Posted in Hepatitis C, Indian Patent Law, Sofosbuvir, Uncategorized | Leave a comment

Why India must beware the side-effects of Pacific Treaty

December 30, 2015, The Hindu Businessline | ARCHANA JATKAR The scope of the recently concluded Trans-Pacific Partnership Agreement (TPPA) goes well beyond conventional trade concerns. It includes extensive obligations on intellectual property (IP) exceeding the minimum standards of the World … Continue reading

Posted in Patent linkage, Patent Term Extension, Sec 3 (d), TPP, TRIPS flexibilities, Uncategorized | Leave a comment

No respite for Big Pharma on patents

FINANCIAL EXPRESS| By Banikinkar Pattanayak on December 30, 2015 Dilution of Section 3(d), compulsory licensing unlikely despite US concerns Disappointed with India’s new National IPR Policy, the US has upped the ante for a world-class patenting regime in India, but … Continue reading

Posted in Compulsory Licensing, IPR policy, Sec 3 (d), TRIPS, TRIPS plus, US pressure on India | Tagged , , , , , | Leave a comment